Search Results

You searched for : Nintedanib

	Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg According to IQVIATM sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales ... Jun 25
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases Cipla Limited today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis ... Oct 21
	Glenmark introduces a generic version of NINDANIB for the treatment of Pulmonary Fibrosis Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version for the treatment of Pulmonary ... Oct 14
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	INBUILDÂ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1 New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive ... Oct 01
6 Matching result(s) found!

-Advertisements-

Trending Now
	MAGGI Empowers 10 Women to Bring their Entrepreneurial dreams to lifeJune 13, 2024
	FTCCI announced its Annual Excellence Awards and invites entries, last date is 20th June 2024June 13, 2024
	Bird Flu Cases by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.June 13, 2024
	Sova Health's $1 Million Seed Funding to Drive Gut Health InnovationJune 13, 2024
	The Vital Role of Early Detection: Kevin Jonas on Battling Skin CancerJune 13, 2024
	Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 AntibodyJune 13, 2024
	HP Ghosh Hospital Unveils Innovative "Chest Tree" June 12, 2024
	Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, IndiaJune 12, 2024
	From the frontlines: Homeless person won over alcoholism, survived floods and defeated TBJune 12, 2024
	The Role of Hormones in Obesity: Why Men and Women Gain Weight DifferentlyJune 12, 2024
	Silent Killer: How a Young Mother’s Vision Loss Led to a Lung Cancer DiagnosisJune 12, 2024
	TruAlt Bioenergy’s subsidiary, Leafiniti Bioenergy supplies over 1000 tons of Compressed Biogas to AG&P Pratham in just 5 monthsJune 11, 2024
	Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in SingaporeJune 11, 2024
	Poor Muscle Health in Obesity Can be A Major Risk Factor for Early DeathJune 11, 2024
	Machine Learning Uncovers How Organ Ageing Impacts Health and LongevityJune 11, 2024
	Why Education is Essential for Health and LongevityJune 11, 2024
	New Study Reveals Antidepressant Withdrawal Symptoms Less Common but Still SignificantJune 10, 2024
	Why Lowering Salt Intake Might Help Your Skin: Key Findings from UCSF StudyJune 10, 2024
	Exploring AI's Potential: I&B Ministry's Seminar on Jobs and Healthcare AdvancementsJune 10, 2024
	Deeply saddened by the passing away of Sri Ramoji Rao GaruJune 08, 2024

Search Results

Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases

Glenmark introduces a generic version of NINDANIB for the treatment of Pulmonary Fibrosis

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

INBUILDÂ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1

Trending Now